FDA Announces Voluntary Recall of Medicines Containing Valsartan Following Detection of Cancer Causing Ingredient

Jul 15, 2018 | FDA Recalls, Zhejiang Huahai Pharmaceuticals

TrialSite News has read that FDA’s announcement occurred several days after other countries conducted their respective recalls of valsartan.  A European Medicines Agency (EMA) review had discovered that valsartan supplied by China-based Zhejiang Huahai Pharmaceuticals http://en.huahaipharm.com/content.asp?info_kind=001002 contained NDMA. https://en.wikipedia.org/wiki/N-Nitrosodimethylamine

View article here

Source: FDA


Pin It on Pinterest